Abstract:Despite continuous improvement of immunosuppressive drugs and appropriate clinical protocols in transplantation medicine, chronic graft rejection and long-term side effects of immunosuppression (IS) still represent major hurdles after kidney transplantation (KTx) (1, 2). Recent research projects in this field therefore focus on induction of tolerance after solid organ transplantation (SOT). Different approaches for establishment of tolerance have been pursued in the past (3). Clinical trials applying nonmyeloablative conditioning combined with donor-cell infusion and simultaneous KTx have reported promising results (4, 5). Nevertheless, most comprehensive clinical data concerning tolerance still exist from patients with two-step bone marrow transplantation (BMT) and SOT (6, 7). However, the number of reported cases of SOT after haploidentical BMT from the same donor is limited (8, 9), but an IS-free long-term graft survival could be demonstrated (10–12). So far, BMT from the same donor before SOT is the only option to reliably provide tolerance, but BMT itself is associated with possible life-threatening side effects (13). Thus, as long as efficient protocols for induction of tolerance are missing, there is the need to identify patients suitable for reduction or withdrawal of IS without risk of graft rejection. Here, we report on a case of KTx in a 23-year-old woman more than 20 years after haploidentical BMT from the same living-related donor (her mother). With help of this unusual case, we were able to prove a difference between tolerance after haploidentical BMT and hyporesponsiveness to human leukocyte antigen (HLA)-matched donor cells with and without ongoing IS. For this, recipient's peripheral blood mononuclear cells (PBMCs) obtained 6 weeks before and after IS withdrawal were used for mixed lymphocyte culture and ELISpot applying third-party controls (n=11) with diverse numbers of HLA mismatches (0–6) as previously described (14). Concerning the medical history of this patient, she had severe combined immunodeficiency syndrome and received allogeneic haploidentical BMT from her mother within the first year of life due to GvHD following maternofetal transfusion syndrome. She developed renal insufficiency at the age of 10. Following 2 years of dialysis, she was transplanted with a fully matched (HLA-A, -B, and -DR alleles) kidney from a deceased donor. This organ was lost due to recurrent infections 8 years after KTx. Subsequently, the patient's mother (the bone marrow donor 22 years ago) provided her organ to the daughter in August 2010. KTx was performed at the University Hospital Hamburg-Eppendorf with initial graft function and IS consisting of low-dose cyclosporine A (CsA) and steroids. IS was stopped 10 weeks after KTx without any episodes of acute rejection (Fig. 1A). The patient has stable kidney function for more than 1 year.FIGURE 1: (A) Function of the transplanted kidney is shown as represented by serum creatinine (black line) and clearance of creatinine (gray bars). The blood levels of cyclosporine A (CsA, dashed line) are depicted for the period of intake, and the time points of steroid and CsA withdrawal are marked (↓). Blood sampling for in vitro testing was performed before and after withdrawal of IS as indicated (*). (B) Representative results of the proliferative responses after stimulation with donor and third party (one each for 0, 2, 3, 4, 5, and 6 MM) are displayed as stimulation index with respect to the autologous control. (C) Frequency of interferon-γ-producing cells after stimulation with donor or third-party antigens (0, 3, and 6 MM, respectively) as measured by ELISpot technique is shown. Data are presented as mean±standard deviation from triplicate cultures before (white bars) and after (black bars) withdrawal of immunosuppression. R=responder, D=donor, 3rd=third party, MM=mismatch, =irradiated.Before secondary KTx, B- and T-cell crossmatchings, screening for cytotoxic antibodies, and HLA antibody measurement (Luminex) were all negative. HLA typing of donor and recipient showed a complete chimerism in the peripheral blood while the tissue of mother and daughter is haploidentical. In vitro testing showed that no differences in T-cell proliferation were observed when comparing the autologous control to donor PBMCs (5406±1408 vs. 5414±1344 cpm, respectively). Interestingly, even stimulation with PBMCs of a HLA-matched third-party control (full match of HLA-A, -B, and -DR alleles) resulted in a significantly increased proliferative response (factor 3.4) when compared with stimulation with donor antigen (18,410±1429 vs. 5414±1344 cpm; P=0.014). At the same time, the response to various third-party controls was found to be maintained. After stimulation with irradiated PBMCs of third-party controls with two to six HLA mismatches with the recipient (n=2 for each group of mismatches), strong T-cell alloreactivity by recipient's cells of at least factor 5.3 was detected (Fig. 1B). Applying ELISpot, we further found that before IS withdrawal only few interferon-γ-producing cells could be detected after stimulation with donor PBMCs (12.0±14.0 cells/1×105 PBMCs). Frequencies of interferon-γ- producing cells in response to PBMCs of healthy volunteers with no HLA mismatches to the recipient (0MM) as well as three (3MM) or six (6MM) mismatches were significantly higher (65.2±20.9 vs. 328.3±4.8 vs. 154.0±7.5 cells/1×105 PBMCs, respectively; P=0.022; Fig. 1C). After IS withdrawal, comparable trends for T-cell alloreactivity and frequency of interferon-γ-producing T cells as initially observed under IS were found among the different groups (Fig. 1B,C). In conclusion, with help of this case of a young woman tolerant to a kidney graft 22 years after allogeneic haploidentical BMT from the same donor, we were able to demonstrate a clear discrimination of tolerance and low immune responsiveness to HLA-identical third-party control. As detection thereof is possible by simple, well-known immunological in vitro assays with and without ongoing IS, these data might help to select patients suitable for further reduction or withdrawal of IS. On the road to induction of tolerance, this approach thus might allow further optimization of individualized IS to reduce side effects and also prevent chronic rejection in patients deemed hyporesponsive rather than tolerant. Florian W. R. Vondran Thomas Eiermann Friedrich Thaiss Reinhard Schwinzer Björn Nashan Martina Koch Transplant Laboratory Department of General, Visceral and Transplantation Surgery Hannover Medical School Hannover, Germany HLA Laboratory University Hospital Hamburg-Eppendorf Hamburg, Germany Departments of Internal Medicine and Nephrology University Hospital Hamburg-Eppendorf Hamburg, Germany Department of Hepatobiliary and Transplantation Surgery University Hospital Hamburg-Eppendorf Hamburg, Germany ACKNOWLEDGMENT The authors thank Sonja Kollrich for her technical assistance.

Response to Comments Made by Atif on “in Vitro and in Vivo Proof of Tolerance after Two-Step Haploidentical Bone Marrow and Kidney Transplantation of the Same Donor”

In Vitro and in Vivo Proof of Tolerance after Two-Step Haploidentical Bone Marrow and Kidney Transplantation of the Same Donor.

Tolerance Induction in Clinically Relevant Transplant Models – Immune Monitoring and Therapeutic Optimisation

Transplantation tolerance

Twenty years in the making: tolerance in a living-related kidney transplant recipient

Positive Long-Term Outcome of Kidney Allocation via Acceptable Mismatch Program in Highly Sensitized Patients

Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients

Pretransplantation Blood Transfusion Revisited

Abo-Incompatible Living Kidney Transplantation

Editorial: Methods in alloimmunity and transplantation: 2023

Transplantation tolerance: don't forget about the B cells

Metastable tolerance in nonhuman primates and humans

Veto cells in transplantation tolerance 1

Monitoring the operationally tolerant liver allograft recipient

Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies

Transplantation tolerance correlates with high levels of T- and B-lymphocyte activity.

Hematopoietic stem cell transplantation induces immunologic tolerance in renal transplant patients via modulation of inflammatory and repair processes

HLA molecular mismatches and induced donor-specific tolerance in combined living donor kidney and hematopoietic stem cell transplantation

A Given Number of Effector T Cells Can Only Destroy a Limited Number of Target Cells in Graft Rejection

Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells with Therapeutic Prospects

Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients